Pharmacokinetics of Quinine, Chloroquine and Amodiaquine: Clinical Implications

Clinical Pharmacokinetics

Volumn 30, Issue 4, 1996, Pages 263-299

  Krishna, Sanjeev ^a   White, Nicholas J ^b,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMOPYROQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; CINCHONA ALKALOID; OROSOMUCOID; QUININE;

DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSFORMATION; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALARIA; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

AMODIAQUINE; ANTIMALARIALS; CHLOROQUINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; MALARIA, FALCIPARUM; MOLECULAR CONFORMATION; QUINIDINE; QUININE;

EID: 0030007219     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630040-00002     Document Type: Article

References (266)

1. Loevinsohn M. Climatic warming and increased malaria incidence in Rwanda. Lancet 1994; 343: 714-8
2. Sharma VP. Epidemiology and control of malaria. The Eighth Asian Congress of Pediatrics: 1994 Feb 6-11; New Delhi
3. Schuster BG, Milhous WK. Reduced resources applied to antimalarial drug development. Parasitol Today 1993; 9: 167-8
4. Alonso PL, Smith T, Armstrong Schellenberg JRM, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344: 1175-81
5. White NJ. Tough test for malaria vaccine. Lancet 1994; 344: 1172-3
6. Maurice J. Malaria vaccine raises a dilemma. Science 1995; 267: 320-3
7. Shepard DS, Ettling MB, Brinkman U, et al. The economic cost of malaria in Africa. Trop Med Parasitol 1991; 42: 199-203
8. Foster SD. Pricing, distribution, and use of antimalarial drugs. Bull World Health Organ 1991; 69: 349-63
9. Nosten F, Price RN. New antimalarials. A risk-benefit analysis. Drug Saf 1995; 12: 264-73
10. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 1992; 30: 571-85
11. Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy. Trans R Soc Trop Med Hyg 1994; 88: 324-7
12. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187-215
13. White NJ, Miller KD, Churchill FC, et al. Chloroquine treatment of severe malaria in children. N Engl J Med 1988; 319: 1493-500
14. Davis TME, Supanaranond W, Pukrittayakamee S, et al. A safe and effective consecutive-infusion regimen for rapid quinine loading in severe malaria. J Infect Dis 1990; 161: 1305-8
15. Edwards G, Winstanley PA, Ward SA. Clinical pharmacokinetics in the treatment of tropical disease. Clin Pharmacokinet 1994; 27: 150-65
16. Winstanley PA, Watkins WM. Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malaria. Br J Clin Pharmacol 1992; 33: 575-81
17. White NJ. Drug treatment and prevention of malaria. Eur J Clin Pharmacol 1988; 34: 1-14
18. White NJ, Krishna S. Treatment of malaria: some considerations and limitations of current methods of assessment. Trans R Soc Trop Med Hyg 1989; 83: 767-77
19. White NJ. The clinical evaluation of antimalarial treatment response. Acta Leiden 1991; 60: 141-6
20. White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992; 34: 1-10
21. White NJ, Nosten F. Advances in chemotherapy and prophylaxis of malaria. Curr Opin Infect Dis 1993; 6: 323-30
22. World Health Organization. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84: 1-65
23. Wyler DJ. Malaria: overview and update. Clin Infect Dis 1993; 16: 449-58
24. Peters W. Chemotherapy and drug resistance in malaria. 2nd ed. London: Academic Press, 1987: 1100
25. Milord F, Allard R, Gyorkos TW. Malaria chemoprophylaxis. Lancet 1993; 342: 502
26. Meagher PD. Guidelines for malaria prophylaxis. Med J Aust 1994; 160: 45-6
27. Krogstad DJ, Herwaldt BL, Schlesinger PH. Antimalarial agents: specific treatment regimens. Antimicrob Agents Chemother 1988; 32: 957-61
28. Karbwang J, White NJ. Clinical importance of antimalarial pharmacokinetics. Asia Pac J Pharmacol 1988; 3: 181-9
29. Kain K. Antimalarial chemotherapy in the age of drug resistance. Curr Opin Infect Dis 1993; 6: 803-11
30. Gilles HM, Warrell DA. Bruce-Chwatt's essential malariology. London: Edward Arnold, 1993: 340
31. Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull World Health Organ 1994; 72: 89-99
32. Panisko DM, Keystone JS. Treatment of malaria: 1990. Drugs 1990; 39: 160-89
33. Kozarsky PE, Lobel HO. Antimalarial agents: are we running out of options? Curr Sci 1994; 7: 701-7
34. Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther 1991; 50: 95-121
35. Wernsdorfer WH. The development and spread of drug-resistant malaria. Parasitol Today 1991; 7: 297-303
36. Herwaldt BL, Krogtstad DJ, Schlesinger PH. Antimalarial agents: specific chemoprophylaxis regimens. Antimicrob Agents Chemother 1988; 32: 953-6
37. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today 1988; 4: 112-5
38. Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 1990; 84: 177-80
39. Bjorkman A, Phillips-Howard PA. Drug-resistant malaria: mechanisms of development and inferences for malaria control. Trans R Soc Trop Med Hyg 1990; 84: 323-4
40. Foote SJ, Cowman AF. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop 1994; 56: 157-71
41. Basco LK, Ruggeri C, Le Bras J. Molecules antipaludiques. Paris: Masson, 1993: 364
42. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 1986; 11: 387-401
43. Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430-75
44. Bryson HM, Goa KL. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 43: 236-58
45. Karle JM, Karle IL, Gerena L, et al. Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother 1992; 36: 1538-44
46. Yennawar MA, Viswamitra MA. Amodiaquine. Curr Sci 1991; 61: 39
47. Jarcho S. Quinine's predecessor. In: Tosti F, editor. The early history of cinchona. The Henry E. Sigerist series in the history of medicine. Baltimore (MD): Johns Hopkins University Press, 1993: 354
48. Slater AFG. Chloroquine: mechanisms of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993; 57: 203-35
49. ter Kuile FO, White NJ, Holloway PA, et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of antimalarials used for the treatment of severe malaria. Exp Parasitol 1993; 76: 85-95
50. Barnes DA, Foote SJ, Galatis D, et al. Selection for high-level chloroquine resistance results in deamplification of the pfmdr 1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 1992; 11: 3067-75
51. Oleksyn BJ, Suszko-Purzycka A, Dive G, et al. Molecular properties of Cinchona alkaloids: a theoretical approach. J Pharm Sci 1992; 81: 122-7
52. Warhurst DC. Cinchona alkaloids and malaria. Acta Leiden 1987; 55: 53-64
53. Druilhe P, Brandicourt O, Chongsuphajaisiddhi T, et al. Activity of a combination of three cinchona bark alkaloids against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 1988 Feb; 32: 250-4
54. Wesche DL, Black J. A comparison of the antimalarial activity of the cinchona alkaloids against Plasmodium falciparum in vitro. J Trop Med Hyg 1990; 93: 153-9
55. Dollery C. Therapeutic drugs. II. Edinburgh: Churchill-Livingstone, 1991: Q8-11
56. White NJ. The pharmacokinetics of quinine and quinidine in malaria. Acta Leiden 1987; 55: 65-76
57. Mihaly GW, Ching MS, Klejn MB, et al. Differences in the binding of quinine and quinidine to plasma proteins. Br J Clin Pharmacol 1987; 24: 769-74
58. Mberu EK, Ward SA, Winstanley PA, Watkins WM. Measurement of quinine in filter paper-absorbed blood by high-performance liquid chromatography. J Chromatogr 1991; 570: 180-4
59. Silamut K, Hough R, Eggelte T, et al. Simple methods for assessing quinine pre-treatment in acute malaria. Trans R Soc Trop Med Hyg 1995; 89: 665-7
60. Vozeh S, Bindscheler M, Huy-Riêm H, et al. Pharmacodynamics of 3-hydroxyquinidine alone and in combination with quinidine in healthy persons. Am J Cardiol 1987; 59: 681-4
61. Kavanagh KM, Wyse G, Mitchell LB, et al. Contribution of quinidine metabolites to electrophysiologic responses in human subjects. Clin Pharmacol Ther 1989; 46: 352-8
62. Berlin CM, Stackman JM, Vesell ES. Quinine-induced alterations in drug disposition. Clin Pharmacol Ther 1975 Dec; 18: 670-9
63. Garnham JC, Raymond K, Shotton E, et al. The bioavailability of quinine. J Trop Med Hyg 1976; 32: 19-23
64. Trenholme GM, Williams RL, Rieckmann KH, et al. Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther 1976; 19: 459-67
65. Sabchareon A, Chongsuphajaisiddhi T, Attanath P. Serum quinine concentrations following the initial dose in children with falciparum malaria. Southeast Asian J Trop Med Public Health 1982; 13: 556-62
66. While NJ, Looareesuwan S, Warrell DA, et al. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated malaria. Am J Med 1982; 73: 564-72
67. White NJ, Chantavanich P, Krishna S, et al. Quinine disposition kinetics. Br J Clin Pharmacol 1983; 16: 399-403
68. Wanwimolruk S, Sunbhanich M, Pongmarutai M, et al. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol 1986; 22: 346-50
69. Jamaludin A, Mohamad M, Navaratnam V, et al. Relative bioavailability of the hydrochloride, sulphate and ethyl carbonate salts of quinine. Br J Clin Pharmacol 1988 Feb; 25: 261-3
70. Salako LA, Sowunmi A, Akinbami FO. Pharmacokinetics of quinine in African children suffering from kwashiorkor. Br J Clin Pharmacol 1989; 28: 197-201
71. Wanwimolruk S, Chalcroft S. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. Br J Clin Pharmacol 1991; 32: 617-20
72. Wanwimolruk S, Chalcroft S, Coville PF, et al. Pharmacokinetics of quinine in young and elderly subjects. Trans R Soc Trop Med Hyg 1991; 85: 714-7
73. Wanwimolruk S, Kaewvichit S, Tanthanyaphinant O, et al. Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. Br J Clin Pharmacol 1991; 31: 179-81
74. Salako LA, Sowunmi A. Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. Eur J Clin Pharmacol 1992; 42: 171-4
75. Paintaud G, Alvan G, Ericsson O. The reproducibility of quinine bioavailability. Br J Clin Pharmacol 1993; 35: 305-7
76. Karbwang J, Davis TME, Looareesuwan S, et al. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br J Clin Pharmacol 1993; 35: 265-71
77. Wanwimolruk S, Wong SM, Coville PF, et al. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol 1993; 36: 610-4
78. Karbwang J, Thanavibul A, Molunto P, et al. The pharmacokinetics of quinine in patients with hepatitis. Br J Clin Pharmacol 1993; 35: 444-6
79. Dyet JR, Davis TME, Giele C, et al. The pharmacokinetics and pharmacodynamics of quinine in diabetic and non-diabetic elderly. Br J Clin Pharmacol 1994; 38: 205-12
80. Hall AP, Czerwinski AW, Madonia EC, et al. Human plasma and urine quinine levels following tablets, capsules, and intravenous infusion. Clin Pharmacol Ther 1973; 14: 580-5
81. Salem SAM, Stevenson IH. Absorption kinetics of aspirin and quinine in elderly subjects. Proceedings of the British Pharmacological Society: 1977 Mar 30-31: Br J Clin Pharmacol 1977; 397P
82. Taggart JV, Earle DP, Berliner RW, et al. Studies on the chemotherapy of human malarias. III. The physiological disposition and antimalarial activity if the cinchona alkaloids. J Clin Invest 1948; 27: 80-6
83. Gonzales FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Clin Pharmacokinet 1994; 26: 59-70
84. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984; 34: 73-80
85. Halliday RC, Jones BC, Smith DA, et al. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995; 40: 369-78
86. Nielsen MD, Brøsen K, Gram LF. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 1990; 29: 299-304
87. Edwards DJ, Axelson JE, Visco JP, et al. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients. Br J Clin Pharmacol 1987; 23: 351-4
88. Oates NS, Fehe MD, Perry HE, et al. Influence of quinidine on nifedipine plasma phamacokinetics. Proceedings of the British Pharmacological Society; 1988 Jan 6-8: Br J Clin Pharmacol 1988; 675P
89. Suphakawanich W, Thithapandha A. Inhibition of hepatic drug metabolism by quinine. Asia Pac J Pharmacol 1987; 2: 241-7
90. Munafo A, Reymond-Michel G, Biollaz J. Altered flecainide disposition in healthy volunteers taking quinine. Eur J Clin Pharmacol 1990; 38: 269-73
91. Amabeoku GJ, Chikuni O, Akino C, et al. Pharmacokinetic interaction of single doses of quinine and carbemazepine, phenobarbitone and phenytoin in healthy volunteers. East Afr Med J 1993; 70: 90-3
92. Spinler SA, Cheng JWM, Kindwall KE. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995; 57: 89-94
93. Jaeger A, Saunder P, Kopferschmitt J, et al. Clinical features and management of poisoning to antimalarial drugs. Med Toxicol 1987; 2: 242-73
94. Lockey D, Bateman DN. The effect of oral activated charcoal on quinine elimination. Br J Clin Pharmacol 1989; 27: 92-4
95. Hachfi-Soussi F, Coudert V, Biron R, et al. Intoxication aiguë à la quinine traitée par diazepam à forte dose. Arch Fr Paediatr 1993; 50: 485-8
96. Doering W, Wilkerson RD. Is there a clinically relevant interaction between quinine and digoxin in human beings? Am J Cardiol 1981; 48: 975-6
97. Aronson J, Carver JG. The interaction of digoxin with quinine. Lancet 1981; I: 1418
98. Notterman DA, Drayer DE, Metakis L, et al. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986 Nov; 40 (5): 511-7
99. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol 1983; 5: 173-5
100. Phillips RE, Warrell DA, White NJ, et al. Intravenous quinidine for the treatment of severe falciparum malaria. N Engl J Med 1985; 312: 1273-8
101. Alvan G, Karlsson KK, Hellgren U, et al. Hearing impairment related to plasma quinine concentration in healthy volunteers. Br J Clin Pharmacol 1991; 31: 409-12
102. Powell RD, McNamara JV. Quinine: side effects and plasma levels. Proc Helm Soc Wash 1972; 39: 331-8
103. Hall AP, Hanchalay S, Doberstyn E, et al. Quinine dosage and serum levels in falciparum malaria. Annual Report of SEATO Medical Research Laboratories. SEATO 1975; 241-50
104. Shann F, Stace J, Edstein M. Pharmacokinetics of quinine in children. J Pediatr 1985; 106: 506-11
105. Phillips RE, Looareesuwan S, White NJ, et al. Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br J Clin Pharmacol 1986; 21: 677-83
106. Wattanagoon Y, Phillips RE, Warrell DA, et al. Intramuscular loading dose of quinine for falciparum malaria: pharmacokietics and toxicity. BMJ 1986; 293: 11-3
107. Davis TME, White NJ, Looareesuwan S, et al. Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. Trans R Soc Trop Med Hyg 1988; 82: 542-7
108. Waller D, Krishna S, Craddock CF, et al. The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1990; 84: 488-91
109. Mansor SM, Taylor TE, McGrath CS, et al. The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans R Soc Trop Med Hyg 1990; 84: 482-7
110. Supanaranond W, Davis TME, Pukrittayakamee S, et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin Pharmacol 1991; 40: 49-52
111. Pasvol G, Newton CRJC, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991; 45: 702-13
112. Winstanley P, Newton C, Watkins W, et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Trans R Soc Trop Med Hyg 1993; 87: 201-6
113. Winstanley PA, Mberu EK, Watkins WM, et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: unbound quinine concentrations following a simple loading dose regimen. Trans R Soc Trop Med Hyg 1994; 88: 577-80
114. Krishna S, Agbenyega T, Angus BJ, et al. Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. Q J Med 1995; 88: 341-9
115. Barennes H, Kahiatani F, Pussard E, et al. Intrarectal Quinimax™ (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. Trans R Soc Trop Med Hyg 1995; 89: 418-21
116. Silamut K, Molunto P, Ho M, et al. α1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 1991; 32: 311-5
117. Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, α1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol 1992; 44: 806-11
118. Mansor SM, Molyneux ME, Taylor TE, et al. Effect of Plasmodium falciparum malaria infection on the plasma concentration of a1-acid glycoprotein and the binding of quinine in Malawian children. Br J Clin Pharmacol 1991; 32: 317-21
119. Kwiatkowski D, Hill AVS, Sambou I, et al. TNF concentrations and disease severity in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990; 336: 1201-04
120. Krishna S, Waller D, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994; 88: 67-73
121. Barnett JA, Brenner DE, Creaven PJ, et al. Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to α1-acid glycoprotein. Br J Clin Pharmacol 1989; 27: 257-61
122. White NJ, Looareesuwan S, Silamut K. Red cell quinine concentrations in falciparum malaria. Am J Trop Med Hyg 1983; 32: 456-60
123. Fremstad D, Jacobsen S. Binding of quinidine in serum and heart from normal and anuric rats, and the significance for distribution. Biochem Pharmacol 1979; 28: 2611-6
124. Ceithaml Jr J, Evans EA. The biochemistry of the malaria parasite VII. In vitro studies on the distribution of quinine between blood cells and their suspending medium. Arch Biochem Biophys 1946; 30: 397-416
125. Benna JE, Pasquier C, Labro MT. Quinine uptake by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1991; 1991: 1474-8
126. Taylor TE, Borgstein A, Molyneux ME. Acid-base status in paediatric Plasmodium falciparum malaria. Q J Med 1993; 86: 99-109
127. Supanaranond W, Davis TME, Pukrittayakamee S, et al. Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. Eur J Clin Pharmacol 1993; 44: 325-9
128. White NJ, Looareesuwan S, Warrell DA, et al. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 1983; 32: 1-5
129. White NJ. Optimal regimens of parenteral quinine. Trans R Soc Trop Med Hyg 1995; 85: 462-3
130. Winstanley PA, Pasvol G, Marsh K. Quinine dose recommendations in childhood malaria: a reply. Trans R Soc Trop Med Hyg 1995; 89: 463-4
131. Mapaba E, Hellgren U, Landberg-Lindgren A, et al. Suscepibility of Plasmodium falciparum to quinine in vitro: effects of drug concentrations and time of exposure. Trans R Soc Trop Med Hyg 1995; 89: 85-9
132. Fargier J-J, Louis FJ, Cot M, et al. Reduction of coma by quinine loading dose in falciparum cerebral malaria. Lancet 1991; 338: 896-7
133. Bateman DN, Dyson EH. Quinine toxicity. Adverse Drug React Acute Poisoning Rev 1986; 4: 215-33
134. Waller D, Krishna S, Crawley J, et al. The outcome and course of severe malaria in Gambian children. Clin Infect Dis 1995; 21: 577-87
135. White NJ, Warrell DA, Chantavanich P, et al. Severe hypoglycaemia and hyperinsulinaemia in falciparum malaria. N Engl J Med 1983; 309: 61-6
136. Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. BMJ 1986; 292: 1319-21
137. Okitolonda W, Delacollette C, Malengreau M, et al. High incidence of hypoglycaemia in African patients treated with intravenous quinine. BMJ 1987; 295: 716-8
138. Das BS, Satpathy SK, Mohanty D, et al. Hypoglycaemia in severe falciparum malaria. Trans R Soc Trop Med Hyg 1988; 82: 197-201
139. Jones RG, Sue-Ling HM, Kear C, et al. Severe symptomatic hypoglycaemia due to quinine therapy. J R Soc Med 1986 Jul; 79 (7): 426-8
140. Davis TME, Looareesuwan S, Pukrittayakamee S, et al. Glucose turnover in severe falciparum malaria. Metabolism 1993; 42: 334-40
141. Davis TME, Suputtamongkol Y, Spencer JL, et al. Glucose turnover in pregnant women with acute malaria. Clin Sci 1994; 86: 83-90
142. White NJ, Miller KD, Marsh K, et al. Hypoglycaemia in African children with severe malaria. Lancet 1987; I: 708-11
143. Taylor TE, Molyneux ME, Wirima JJ, et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 1988; 319: 1040-7
144. While NJ. Pathophysiology. In: Strickland GT, editor. Clinics in tropical medicine and communicable diseases. London: Saunders, 1986: 55-90
145. Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med 1985; 214: 125-31
146. Luzzi GA, Peto TEA. Adverse effects of antimalarials: an update. Drug Saf 1993; 8: 295-311
147. Chongsuphajaisiddhi T, Sabchareon A, Attanath P. Treatment of quinine resistant falciparum malaria in Thai children. Southeast Asian J Trop Med Public Health 1983; 14: 357-62
148. Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet 1985 Jul; 11: 4-8
149. Davis TME, Spanaranond W, Pukrittayakamee S, et al. Glucose tolerance in pregnant patients with acute falciparum malaria. Trans R Soc Trop Med Hyg 1993; 87: 666-7
150. Looareesuwan S, White NJ, Silamut K, et al. Quinine and severe falciparum malaria in late pregnancy. Acta Leiden 1987; 55: 115-20
151. Looareesuwan S, Phillips RE, Karbwang J, et al. Plasmodium falciparum hyperparasitaemia: use of exchange transfusion in seven patients and a review of the literature. Q J Med 1990; 75: 471-81
152. Sanders JP, Dawson WT. Efficacy of quinidine in malaria. JAMA 1932; 99: 1773-7
153. Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med 1989; 321: 65-70
154. Rudnitsky G, Miller KD, Padua T, et al. Continuous-infusion quinidine gluconate for treating children with severe Plasmodium falciparum malaria. J Infect Dis 1987; 155: 1040-3
155. Bruce-Chwatt LJ. Chemotherapy of malaria. 2nd ed. Geneva: WHO, 1981: 260
156. Most H, London IM, Kane CA, et al. Chloroquine for treatment of acute attacks of vivax malaria. JAMA 1946; 131: 963-7
157. Pussard E, Verdier F. Antimalarial 4-aminoquinolines: mode of action and pharmacokinetics. Fundam Clin Pharmacol 1994; 8: 1-17
158. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Java, Indonesia. Am J Trop Med Hyg 1991; 44: 547-52
159. Collignon P. Chloroquine resistance in Plasmodium vivax. J Infect Dis 1991; 164: 222-3
160. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341: 96-100
161. Myat-Phone-Kyaw, Myint-Oo, Myint-Lwin, et al. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg 1993 Nov-Dec; 87: 687
162. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989 Nov; II: 1183-4
163. Schuurkamp GJ, Spicer PE, Kereu RK, et al. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 1992; 86: 121-2
164. Schwartz IK, Lackritz EM, Patchen LC. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med 1991; 324: 927
165. Thaithong S, Suebsaeng L, Rooney W, et al. Evidence of increased chloroquine sensitivity in Thai isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1988; 82: 37-8
166. Wernsdorfer WH, Landgraf B, Wiedermann G, et al. Chloroquine resistance of Plasmodium falciparum: a biological advantage. Trans R Soc Trop Med Hyg 1995; 89: 90-2
167. Fink vE, Minet G, Nickel P. Chloroquin-Enantiomere. Arzneimittel Forschung 1979; 29: 163-4
168. Fu S, Bjorkman A, Wahlin B, et al. In vitro activity of chloroquine, the enantiomers of chloroquine, desethylchloroquine and pyronaidine against Plasmodiuum falciparum. Br J Clin Pharmacol 1986; 22: 93-6
169. Aderounmu FA. In vitro assessment of the antimalarial activity of chloroquine and its major metabolites. Ann Trop Med Parasitol 1984; 78: 581-5
170. Verdier F, Le Bras J, Clavier et al. Blood levels and in vitro activity of desethylchloroquine against Plasmodium falciparum [letter]. Lancet 1984 May 26; 1: 1186-7
171. Slater AFG, Cerami A. Inhibition by chloroquine of a novel haem polymerase activity in malaria trophozoites. Nature 1992; 355: 167-9
172. Chou AC, Fitch CD. Heme polymerase: modulation by chloroquine treatment of a rodent malaria. Life Sci 1992; 51: 2073-8
173. Dorn A, Stoffel R, Matile H, et al. Malaria haemozoin/b-haematin supports haem polymerization in the absence of protein. Nature 1995; 374: 269-71
174. Blauer G, Akkawi M. B-hematin. Biochem Mol Biol Int 1995; 35: 231-5
175. Francis SE, Gluzman IY, Oksman A, et al. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J 1994; 13: 306-17
176. Gluzman IY, Francis SE, Oksman A, et al. Order and specificity of the Plasmodium falciparum hemoglobin degredation pathway. J Clin Invest 1994; 93: 1602-8
177. Yayon A, Cabantchik ZI, Ginsburg H. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci USA 1985; 82: 2784-8
178. Krogstad DJ, Schlesinger PH, Gluzman IY. The specificity of chloroquine. Parasitol Today 1992; 8: 183-4
179. Odoula AMJ, Moyou-Somo RS, Kyle DE, et al. Chloroquine resistant Plasmodium falciparum in indigenous residents of Cameroon. Trans R Soc Trop Med Hyg 1989; 83: 308-10
180. Boulter MK, Bray PG, Howells RE, et al. The potential of desipramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Trans R Soc Trop Med Hyg 1993; 87: 303
181. Warsame M, Wernsdorfer WH, Bjorkman A. Lack of effect of desipramine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. Trans R Soc Trop Med Hyg 1992; 86: 235-6
182. Wellems TE. Molecular genetics of drug resistance in Plasmodium falciparum malaria. Parasitol Today 1991; 7: 110-2
183. Kwiatkowski D, Bate C. Inhibition of tumour necrosis factor (TNF) production by antimalarial drugs used in cerebral malaria. Trans R Soc Trop Med Hyg 1995; 89: 215-6
184. Picot S, Peyron F, Donadille A, et al. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993; 80: 127-33
185. Yayon A. The antimalarial mode of action of chloroquine. Rev Clin Basic Pharmacol 1985; 6: 99-139
186. Titus EO. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit 1989; 11: 369-79
187. Smith GD, Amos TAS, Mahler R, et al. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insuline-dependent diabetes mellitus. BMJ 1987; 294: 465-7
188. Asamoah KA, Robb DA, Furman BL. Chronic chloroquine treament enhances insulin release in rats. Diabetes Res Clin Pract 1990; 9: 273-8
189. Patchen LC, Mount DL, Schwartz IK, et al. Analysis of filter-paper-absorbed, finger-stick blood samples for chloroquine and its major metabolite using high performance liquid chromatography with fluorescence detection. J Chromatogr 1983; 278: 81-9
190. Berqvist Y, Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethylchloroquine in human blood cells and its implications for the qualitative determination of these compounds in serum and plasma. J Chromatogr 1983; 221: 119-27
191. Geary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J Trop Med Hyg 1983; 32: 19-23
192. Ajayi F, Salako LA, Kuye JO. Comparison of the partitioning in vitro of chloroquine and its desethylmetabolites between the erythrocytes and plasma of healthy subjects and those with malaria. Afr J Med Sci 1989; 18: 95-100
193. Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol 1986; 22: 356-8
194. Edwards G, Looareewuwan S, Davies AJ, et al. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects with Plasmodium vivax malaria. Br J Clin Pharmacol 1988; 22: 477-85
195. McChesney EW, Fasco MJ, Banks WF. The metabolism of chloroquine in man during and after repeated oral dosage. J Pharmacol Exp Ther 1967; 158: 323-31
196. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. Chloroquine serum concentration and side effects: evidence for dose dependent kinetics. Clin Pharmacol Ther 1979; 25: 345-50
197. Gustaffson LL, Rombo L, Alvan G, et al. On the question of dose-dependent chloroquine elimination of a single dose. Clin Pharmacol Ther 1983; 34: 383-5
198. Gustafsson LL, Walker O, Alvan G, et al. Disposition of chloroquine in man after single intravenous and oral dose. Br J Clin Pharmacol 1983; 15: 471-9
199. Tulpule A, Krishnaswamy K. Chloroquine kinetics in the undernourished. Eur J Clin Pharmacol 1983; 19: 273-6
200. Frisk-Holmberg M, Berqvist Y, Termond E, et al. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol 1984; 26: 521-30
201. Salako LA, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci 1984; 13: 177-82
202. Looareesuwan S, White NJ, Chantavanich P, et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 1986; 22: 31-6
203. Aderounmu AF, Salako LA, Lindstrom B, et al. Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br J Clin Pharmacol 1986; 22: 559-64
204. Rombo L, Bergquist Y, Hellgren U. Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophyaxis. Bull World Health Organ 1987; 65: 879-83
205. Gustafsson LL, Lindstrom B, Grahnen A, et al. Chloroquine excretion following malaria prophylaxis. Br J Clin Pharmacol 1987; 24: 221-4
206. Walker O, Salako LA, Alvan G, et al. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol 1987; 23: 295-301
207. Walker O, Dawodu AH, Salako LA, et al. Single dose disposition of chloroquine in kwashiorkor and normal children-evidence tor decreased absorption in kwashiorkor. Br J Clin Pharmacol 1987; 23: 467-72
208. Salako LA, Aderounmo AF, Walker O. Influence of route of administration on the pharmacokinetics of chloroquine and desethylchloroquine. Bull World Health Organ 1987; 39: 696-9
209. Tett SE, Cutler DJ, Day RO, et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27: 771-9
210. Essien EE, Ette EI, Thomas WOA, et al. Chloroquine disposition in hypersensitive and non-hypersensitive subjects and its significance in chloroquine-induced pruritus. Eur J Drug Metab Pharmacokinet 1989; 14: 71-7
211. Verdier F, Pussard E, Clavier F, et al. Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum. Antimicrob Agents Chemother 1989; 33: 316-21
212. Minker E, Ivan J. Experimental and clinicopharmacological study of rectal absorption of chloroquine. Acta Physiol Hung 1991; 77: 237-48
213. Augustijns P, Verbeke N. Stereoselective pharmacokinetic propoerties of chloroquine and de-ethyl-chloroquine in humans. Clin Pharmacokinet 1993; 24: 259-69
214. Na Bangchang K, Limpaibul L, Thanavibul A, et al. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol 1994; 38: 278-81
215. Wetsteyn JCFM, de Vries PJ, Oosterhuis B, et al. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br J Clin Pharmacol 1995; 39: 696-9
216. Winstanley P, Edwards G, Orme M, et al. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987; 23: 1-7
217. White NJ, Looareesuwan S, Edwards G. et al. Pharmacokinetics of intravenous amodiaquine. Br J Clin Pharmacol 1987; 23: 127-35
218. Pussard E, Verdier F, Faurisson F, et al. Disposition of monodesethylamodiaquine after a singel oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum. Eur J Clin Pharmacol 1987; 33: 409-14
219. Tett SE, Cutter DJ. Apparent dose dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur J Clin Pharmacol 1987; 31: 729-31
220. Tjoeng MM, Hogeman PHG, Kapelle H, et al. Comparative bioavailability of rectal and oral formulations of chloroquine. Pharm Weekbl Sci 1991; 13: 176-8
221. Ette EI, Essien EE, Brown-Awala EE. Pharmacokinetics of chloroquine: saliva and plasma levels relationship. Eur J Drug Metab Pharmacokinet 1986; 11: 275-81
222. Ogubona FA, Lawal AA, Onyeji CO. Saliva secretion of chloroquine in man. J Pharm Pharmacol 1986; 38: 535-7
223. Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Enatioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine. Ther Drug Monit 1986; 8: 457-61
224. Gustafsson LL, Nordmark B, Ericsson O, et al. The pharmacokineticso f (+) and (-) chloroquine in patients with rheumatoid arthritis. Proceedings of the Third World Congress on Clinical Pharmacology and Therapeutics: 1986 Jul; Stockholm
225. Hellgren U, Alvan G, Jerling M. On the question of interindividual variations in chloroquine concentrations. Eur J Clin Pharmacol 1993; 45: 383-5
226. Hellgren U, Kihamia CM, Mahikwano LF, et al. Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull World Health Organ 1989; 67: 197-202
227. Neuvonen PJ, Kivisto KT, Pyykko K. Prevention of chloroquine absorption by activated charcoal. Human Exp Toxicol 1992 Mar; 11: 117-20
228. Mahmoud BM, Ali HM, Homeida MMA, et al. Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and lemon. J Antimicrob Chemother 1994; 33: 1005-9
229. Lancaster DL, Adio RA, Tai KK, et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol 1990; 42: 267-71
230. Bustos MDG, Gay F, Diquet B, et al. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 1994; 45: 83-6
231. Koudogbo B, Asseko MC, Mbina CN, et al. Mode d'action antidotique du diazepam dans le traitment des intoxications a la chloroquine. J Toxicol Clin Exp 1986; 6: 307-12
232. Riou B, Barriot P, Rimailho A, et al. Treatment of severe chloroquine poisoning. N Engl J Med 1988; 318: 1-6
233. Bhasin DK, Chhina RS, Sachdeva JR. Endoscopic assessment of chloroquine phosphate-induced damage to esophageal, gastric, and duodenal mucosa. Am J Gastroenterol 1991; 86: 434-7
234. Ekpechi OL, Okoro AN. A pattern of pruritus due to chloroquine. Arch Dermatol 1964; 89: 631-2
235. Ajayi AA, Oluokun A, Sofowora O, et al. Epidemiology of antimalarial-induced pruritus in Africans. Eur J Clin Pharmacol 1989; 37: 539-40
236. Abila B, Ikueze R. Effects of clemastine, ketotifen and prednisolone on chloroquine-induced pruritus. J Trop Med Hyg 1989; 92: 356-9
237. Ajayi AA, Akinleye AO, Udoh SJ, et al. The effects of prednisolone and niacin on chloroquine-induced pruritus in malaria. Eur J Clin Pharmacol 1991; 41: 383-5
238. Ezcamuzie IC, Igbigbi PS, Ambakederemo AW, et al. Halofantrine-induced pruritus amongst subjects who itch to chlorquine. J Trop Med Hyg 1991; 94: 184-8
239. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988; 85 Suppl. 4A: 23-9
240. Tuffanelli D, Abraham RK, Dubois EI. Pigmentation from antimalarial therapy. Arch Dermatol 1963; 88: 113-20
241. Lange WR, Frankenfield DL, Moriarty-Sheehan M, et al. No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg 1994; 51: 389-92
242. Adelusi SA, Dawodu AH, Salako LA. Kinetics of the uptake and elimination of chloroquine in children with malaria. Br J Clin Pharmacol 1982; 14: 483-7
243. Walker O, Birkett DJ, Alvan D, et al. Characterisation of chloroquine plasma protein binding in man. Br J Clin Pharmacol 1983; 15: 375-7
244. Phillips RE, Warrell DA, Edwards G, et al. Divided dose intramuscular regimen and single dose subcutaneous regimen for chloroquine: plasma concentrations and toxicity in patients with malaria. BMJ 1986; 293: 13-6
245. White NJ, Watt G, Bergqvist Y, et al. Parenteral chloroquine for treating falciparum malaria. J Infect Dis 1987; 155: 192-201
246. Winstanley PA, Simooya O, Kofi-Ekue JM, et al. The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol 1990; 29: 695-701
247. Pussard E, Lepers JP, Clavier F, et al. Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 1991; 35: 406-9
248. Bloland PB, Lackritz EM, Kazembe PN, et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993; 167: 932-7
249. Sudre P, Breman JG, McFarland D, et al. Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis. International J Epidemiol 1992; 21: 146-54
250. Peeters PAM, Huiskamp CWEM, Eling WMC, et al. Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology 1989; 98: 381-6
251. White NJ, Krishna S, Waller D, et al. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet 1988; 11: 1313-5
252. Essien EE, Afamefuna GC. Chloroquine and its metabolites in human cord blood, neonatal blood and urine after maternal medication. Clin Chem 1982; 28: 1148-52
253. Parke A. Antimalarial drugs and pregnancy. Am J Med 1988; 85: 30-3
254. Edstein MD, Veenendaal JR, Newmank K, et al. Chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol 1986; 22: 722-35
255. Ogubona FA. Onyeji CO, Bolaji OO, et al. Excretion of chloroquine and desethylchloroquine in human milk. Br J Clin Pharmacol 1987; 23: 473-6
256. Larrey DAC, Pessayre D, et al. Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986; 104: 801-3
257. Hatton C, Peto T, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; I: 411-4
258. Winstanley P, Coleman JW, Maggs JL, et al. The toxicity of amodiaquine and its principle metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. Br J Clin Pharmacol 1990; 29: 479-85
259. Fadat G, Le Bras J, Hengy et al. Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet 1991; 338: 1092
260. Nevill CA, Verhoef FH, Munafu CG, et al. A comparison of amodiaquine and chloroquine in the treatment therapy of falciparum malaria in Kenya. East Afr Med J 1994; 71: 167-70
261. Basco LK. Inefficacy of amodiaquine against chloroquine-resistam malaria. Lancet 1991; 338: 1460
262. Basco LK, Le Bras J. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1993; 48: 120-5
263. Hoekenga MT. Intramuscular amopyroquin for acute malaria. Am J Trop Med Hyg 1962; 11: 1-5
264. Gaudebout C, Pussard E, Clavier F, et al. Efficacy of intramuscular amopyroquin for treatment of Plasmodium falciparum malaria in the Gabon Republic. Antimicrob Agents Chemother 1993; 37: 970-4
265. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341: 848-51
266. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341: 1299-303